Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RESprotect GmbH

www.resprotect.com

Latest From RESprotect GmbH

BioNotebook: Three licenses and a royalty deal; Ligand/Avion, RedHill/RESprotect and more

Summer is for relaxing, but biotechnology companies like Avion Pharmaceuticals and investors like DRI Capital remain focused on licensing key programs or buying new revenue streams.

Infectious Diseases Cancer

RESprotect regains pancreatic anticancer and a green light to resume development

SciClone Pharmaceuticals has returned the North American rights to the anticancer drug RP101 to privately owned German oncology firm RESprotect which it obtained in 2007.

Cancer Japan

Investment gains to advance Acuvax's vaccine ambitions

Acuvax has divested to an unnamed European company its 10% holding in the private German oncology firm RESprotect. The Australian venture retains an interest in RESprotect's lead project, RP101 (BVdU), which is being developed by SciClone Pharmaceuticals.

Cancer

Deals Shaping the Medical Industry (5/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • RESprotect GmbH
  • Senior Management
  • Rudolf Fahrig, PhD, CEO
    Torsten Fahrig, COO & CFO
    Jörg-Christian Heinri, PhD, CSO
    Klaus Kutz, MD, CMO
  • Contact Info
  • RESprotect GmbH
    Phone: (49) 351 20250643
    Krippener Str. 18b
    Dresden, 01259
    Germany
UsernamePublicRestriction

Register